Alpine 4's (ALPP) Subsidiary, Alternative Labs, Adds $2M in New Production Work for June and July Totaling $5.8M in Backlog
Alpine 4 Holdings, Inc. (ALPP) announced that its subsidiary, Alternative Laboratories, secured $2 million in new production orders for June and July 2021, increasing the backlog to nearly $5.8 million. Alt Labs is developing around 40 new formulas and expanding its R&D staff to accommodate new projects. With the addition of new mixing equipment, Alt Labs expects to exceed $22 million in production for 2021, marking a significant improvement over 2020.
- Secured $2 million in new production orders.
- Total backlog now stands at nearly $5.8 million.
- Development of around 40 new formulas indicates business expansion.
- Investment in new equipment and training is expected to boost production to over $22 million for 2021.
- None.
PHOENIX, AZ / ACCESSWIRE / June 4, 2021 / Alpine 4 Holdings, Inc. (OTCQB:ALPP), a leading operator and owner of small market businesses, announces that its subsidiary, Alternative Laboratories, LLC. (ALT LABS), has secured several new production orders adding
Alt Labs is currently working on around 40 new formulas for new and existing customers. The company is in the process of expanding the R&D staff in order to keep up with the influx of new projects. With the addition of a 2nd 800kg double cone blender, Alt labs has more than enough capacity to accommodate its current and new clientele.
Alt Labs is a private label contract manufacturer located in Southwest, Florida, USA. The Company specializes in the manufacturing and packaging of; liquids, powders, tablets, capsules, and other unique nutritionals. Alt Labs has a wide array of customers that sell their products in the USA and internationally through eCommerce platforms like Amazon, as well as, direct business to consumer (B2C) via their own sales networks.
Kent Wilson, CEO of Alpine 4, had this to say, "It's always a pleasure to see a newly added subsidiary firing on all cylinders this quickly after being acquired. These orders add to an already impressive backlog of work for 2021. We appreciate all of the hard work being put forth by the team at Alt Labs!"
Mark Wesolaski, COO of Alternative Labs, had this to say, "With the addition of our new mixing equipment, investments in training, and other capital initiatives, 2021 is already shaping up to be better than 2020. The Company is on track to produce well over
About Alpine 4 Holdings: Alpine 4 Holdings, Inc. (ALPP) is a publicly traded conglomerate that acquires businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. At Alpine 4, we understand the nature of how technology and innovation can accentuate a business. Our focus is on how the adaptation of new technologies, even in brick-and-mortar businesses, can drive innovation. We also believe that our holdings should benefit synergistically from each other, have the ability to collaborate across varying industries, spawn new ideas and create fertile ground for competitive advantages.
Four principles at the core of our business are Synergy. Innovation. Drive. Excellence. At Alpine 4, we believe synergistic innovation drives excellence. By anchoring these words to our combined experience and capabilities, we can aggressively pursue opportunities within and across vertical markets. We deliver solutions that not only drive industry standards, but also increase value for our shareholders.
Contact: Investor Relations
investorrelations@alpine4.com
www.alpine4.com
Forward-Looking Statements: The information disclosed in this press release is made as of the date hereof and reflects Alpine 4 most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.
SOURCE: Alpine 4 Holdings, Inc.
View source version on accesswire.com:
https://www.accesswire.com/650398/Alpine-4s-ALPP-Subsidiary-Alternative-Labs-Adds-2M-in-New-Production-Work-for-June-and-July-Totaling-58M-in-Backlog
FAQ
What new production orders did Alpine 4's subsidiary secure?
What is the total backlog for Alternative Laboratories?
How many new formulas is Alternative Laboratories developing?
What is the expected production revenue for Alternative Laboratories in 2021?
